Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents Sensei Biotherapeutics in Acquisition of Faeth TherapeuticsFebruary 18, 2026Sidley Represents Cherokee Nation Businesses in Its Investment in Front Line Power ConstructionFebruary 18, 2026Sidley Represents Arsenal Capital Partners and MaxHealth in Sale of MaxHealth to CenterWellFebruary 17, 2026Sidley Shortlisted for Deal of the Year and Attorney of the Year at D CEO Mergers & Acquisition Awards 2026February 17, 2026Sidley Represents New Catalyst in Strategic Partnership With Ferghana Investment PartnersFebruary 11, 2026Sidley Represents Great Lakes In Its US$1.5 Billion Acquisition by SaltchukFebruary 11, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory